GSK PLC Sponsored ADR (NYSE:GSK) Shares Sold by Citigroup Inc.

Key Points

• Citigroup Inc. reduced its stake in GSK PLC by 16.6% during the first quarter, holding a total of 216,442 shares valued at approximately $8.39 million after selling 42,963 shares.
• GSK announced a quarterly dividend of $0.4206, providing a yield of 4.3%, despite a payout ratio of 79.17%.
• GSK's latest earnings report showed an EPS of $1.23, surpassing the consensus estimate by $0.11, with revenue of $10.64 billion for the quarter.

Citigroup Inc. trimmed its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 16.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 216,442 shares of the pharmaceutical company's stock after selling 42,963 shares during the quarter. Citigroup Inc.'s holdings in GSK were worth $8,385,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of GSK. HHM Wealth Advisors LLC lifted its holdings in GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after buying an additional 460 shares during the last quarter. Costello Asset Management INC purchased a new stake in GSK during the 1st quarter worth about $31,000. Richardson Financial Services Inc. lifted its holdings in GSK by 127.9% during the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after buying an additional 472 shares during the last quarter. Olde Wealth Management LLC purchased a new stake in GSK during the 1st quarter worth about $36,000. Finally, Cary Street Partners Investment Advisory LLC lifted its holdings in GSK by 525.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after buying an additional 852 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on GSK. Wall Street Zen raised GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Berenberg Bank reissued a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, Hsbc Global Res raised GSK to a "strong sell" rating in a report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, GSK currently has a consensus rating of "Hold" and a consensus price target of $37.38.

GSK Stock Performance

Shares of GSK stock opened at $39.30 on Friday. The stock has a market capitalization of $80.14 billion, a PE ratio of 18.19, a price-to-earnings-growth ratio of 1.71 and a beta of 0.51. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $44.67. The stock's 50-day moving average price is $38.50 and its 200 day moving average price is $37.97. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.11. The firm had revenue of $10.64 billion for the quarter, compared to analysts' expectations of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%. The firm's revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.43 EPS. As a group, equities research analysts forecast that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be given a $0.4206 dividend. This represents a $1.68 annualized dividend and a yield of 4.3%. The ex-dividend date is Friday, August 15th. GSK's payout ratio is 79.17%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.